| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/19/2013 | US8398996 Staphylococcus aureus proteins and nucleic acids |
| 03/19/2013 | US8398984 Removal promoters and inhibitor for apoptosis cells in vivo |
| 03/19/2013 | US8398970 Method of preventing early Lawsonia intracellularis infections |
| 03/19/2013 | US8398969 Compositions and methods for the treatment of viral hepatitis |
| 03/19/2013 | US8398968 Adenoviral expression vectors |
| 03/19/2013 | CA2656259C Process for producing poxviruses and poxvirus compositions |
| 03/19/2013 | CA2536086C Inhibition of dr3 in the treatment of allergic lung inflammation |
| 03/19/2013 | CA2513251C Cancer therapy sensitizer |
| 03/19/2013 | CA2491907C Oncolytic virus replicating selectively in tumor cells |
| 03/19/2013 | CA2440303C Wt1 modified peptide |
| 03/19/2013 | CA2429342C Promoters exhibiting endothelial cell specificity and methods of using same |
| 03/19/2013 | CA2311647C Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 03/19/2013 | CA2195334C Compositions and methods for enhanced tumor cell immunity in vivo |
| 03/14/2013 | WO2013036867A2 Compositions and methods for cancer and cancer stem cell detection and elimination |
| 03/14/2013 | WO2013036799A2 Methods and compositions involving nkg2d inhibitors and cancer |
| 03/14/2013 | WO2013036795A2 Oncolytic herpes simplex virus and therapeutic uses thereof |
| 03/14/2013 | WO2013036791A2 Modified adenoviral vectors and methods of treatment using same |
| 03/14/2013 | WO2013036720A1 Methods for treatment of cancer by targeting sirt5 |
| 03/14/2013 | WO2013036610A2 Compositions comprising mg53 and methods for the treatment and prevention of airway injury |
| 03/14/2013 | WO2013036596A2 Serpinf2-binding molecules and methods of use |
| 03/14/2013 | WO2013036301A1 Induced tolerogenic dendritic cells for inducing regulatory b cells |
| 03/14/2013 | WO2013036300A1 Compositions and methods related to induced tolerogenic dedritic cells externally loaded with mhc class i-restricted epitopes |
| 03/14/2013 | WO2013036295A1 Antigen-specific induced tolerogenic dendritic cells to reduce antibody responses |
| 03/14/2013 | WO2013036294A1 Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses |
| 03/14/2013 | WO2013036282A2 Downregulation of inflammatory micrornas by ilt3 |
| 03/14/2013 | WO2013036031A2 Pharmaceutical composition including a microrna486 expression inhibitor as an active ingredient for preventing and treating neurological disorders |
| 03/14/2013 | WO2013035896A1 Novel uses of kiaa1764 as apoptosis and aging regulator |
| 03/14/2013 | WO2013035895A1 Novel apoptosis regulator |
| 03/14/2013 | WO2013035861A1 Method for determining susceptibility to age-related macular degeneration, primer pair, probe, age-related macular degeneration diagnostic kit, therapeutic agent for age-related macular degeneration, and screening method for therapeutic agent for age-related macular degeneration |
| 03/14/2013 | WO2013035824A1 Cancer stem cell isolation |
| 03/14/2013 | WO2013035757A1 Preparation comprising hexose-6-phosphate-modified cholesterol derivative |
| 03/14/2013 | WO2013035208A1 ANTIBODY AGAINST MUTANT α-ACTININ-4 |
| 03/14/2013 | WO2013035101A1 Compositions of functional mitochondria and uses thereof |
| 03/14/2013 | WO2013034989A2 Microrna-based methods and assays for osteosarcoma |
| 03/14/2013 | WO2013012875A3 Bacterial rnas as vaccine adjuvants |
| 03/14/2013 | WO2012149198A3 A method for manufacturing pegylated oligonucleotides |
| 03/14/2013 | WO2012145653A3 Therapeutic combinations for use in neoplasia |
| 03/14/2013 | WO2012141794A3 Crystal structure and peptide inhibitors of hausp deubiquitinase |
| 03/14/2013 | WO2012141674A3 Compositions and methods relating to argininosuccinate synthetase |
| 03/14/2013 | WO2012138846A3 Method and compositions comprising small rna agonist and antagonists to modulate inflammation |
| 03/14/2013 | WO2012138691A3 Diagnosis and treatment of taxane-resistant cancers |
| 03/14/2013 | WO2012135805A3 Delivery and formulation of engineered nucleic acids |
| 03/14/2013 | WO2012079059A3 Post-treatment breast cancer prognosis |
| 03/14/2013 | US20130066058 Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1 |
| 03/14/2013 | US20130066052 Ucp4 |
| 03/14/2013 | US20130065948 Nucleic acid molecules and methods for exchanging exon(s) by transsplicing |
| 03/14/2013 | US20130065946 Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155 |
| 03/14/2013 | US20130065944 Reverse micelle system comprising nucleic acids and use thereof |
| 03/14/2013 | US20130065942 Nucleic Acid-Lipopolymer Compositions |
| 03/14/2013 | US20130065298 siRNA-MEDIATED GENE SILENCING |
| 03/14/2013 | US20130064965 Implants for administering substances and methods of producing implants |
| 03/14/2013 | US20130064895 Amphiphilic Peptides and Peptide Particles |
| 03/14/2013 | US20130064894 Novel cationic lipids and methods of use thereof |
| 03/14/2013 | US20130064886 Microtablets for Drug Delivery |
| 03/14/2013 | US20130064813 Protein Belonging to the TNF Superfamily Involved in Signal Transduction, Nucleic Acids Encoding Same and Methods of Use Thereof |
| 03/14/2013 | US20130064792 Therapy for influenza like illness |
| 03/14/2013 | CA2846667A1 Serpinf2-binding molecules and methods of use |
| 03/13/2013 | EP2567982A1 Antibody against carcinoembryonic antigen and uses thereof |
| 03/13/2013 | EP2567967A2 Method of using adenoviral vectors to induce an immune response |
| 03/13/2013 | EP2567952A1 Cationic lipid |
| 03/13/2013 | EP2567951A1 Cationic lipid |
| 03/13/2013 | EP2567693A1 Lipid encapsulated interfering RNA |
| 03/13/2013 | CN102971423A Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA |
| 03/13/2013 | CN102971002A Composition for nucleic acid delivery, carrier composition, pharmaceutical composition using the composition for nucleic acid delivery or the carrier composition, and method for delivering nucleic acid |
| 03/13/2013 | CN102965439A Application of miR-296-3p to preparation of kit for diagnosing prostate cancer generation or migration |
| 03/13/2013 | CN102965429A Application of microRNA-320(miR-320A) and its antisense nucleotide in diagnosis, prevention and treatment of cardiovascular diseases |
| 03/13/2013 | CN102965376A N-(3-oxo-dodecanoyl)-L-homoserine lactone aptamer, its screening method and application |
| 03/13/2013 | CN102965372A SiRNA interfering GDF9 gene expression and application thereof |
| 03/13/2013 | CN102965371A SiRNA inhibiting BMP15 gene expression and application thereof |
| 03/13/2013 | CN102965348A Bovine viral diarrhea-mucosal virus with modified erns protein |
| 03/13/2013 | CN102965347A Preparation method of recombinant adeno-associated virus expressing hsa-miR-21<*> and application in treatment of hypertension |
| 03/13/2013 | CN102965341A Immortalized human umbilical cord mesenchymal stem cell line, and construction method and application thereof |
| 03/13/2013 | CN102961759A Targeting gene transferring method of folic acid-functionalized PAMAM (polyamidoamine dendrimers) wrapped by gold nanoparticles |
| 03/13/2013 | CN102961758A Application of CpG-ODN in preparation of drugs for promoting lymphoma cell apoptosis |
| 03/13/2013 | CN102961757A Pseudovirus particle vaccine carrying double-stranded RNA target antigen and neutralizing antigen |
| 03/13/2013 | CN102397560B Preparation method for avian pasteurella genome vaccine |
| 03/13/2013 | CN102382828B PPP2R5C-siRNA991 for targeted inhibition of expression of PPP2R5C genes and multiplication of tumorous T cells and applications thereof |
| 03/13/2013 | CN102234634B High-transduction-efficiency hepatophilic cell hepatitis C virus pseudo-particle and envelope protein coded sequence thereof |
| 03/13/2013 | CN102210873B Application of C10orf116 genes in preparing medicament for improving insulin sensitivity of adipose tissue |
| 03/13/2013 | CN102172406B Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo |
| 03/13/2013 | CN102139116B Preparation method of envelope protein A gene vaccine for fowl cholera |
| 03/13/2013 | CN102060723B Preparation method of cationic liposome nanoparticles of amino acid |
| 03/13/2013 | CN102046190B Therapeutic agent for anaerobic diseases |
| 03/13/2013 | CN102018963B MiR-125a for adjusting regulated on activation normal T cell expressed and secreted (RANTES) expressions as well as composition and application thereof |
| 03/13/2013 | CN101954095B Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
| 03/13/2013 | CN101914541B Inhibitor for inhibiting expression of MBD2 and application thereof |
| 03/13/2013 | CN101851278B B cell activating factor antagonist as well as preparation method and application thereof |
| 03/13/2013 | CN101768214B Human tumor marker-Tim17 polypeptide and application thereof |
| 03/13/2013 | CN101748096B Sub totipotential stem cell and preparation method and application thereof |
| 03/13/2013 | CN101384716B HLA-a*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
| 03/12/2013 | US8394930 Growth factor isoform |
| 03/12/2013 | US8394777 Treating immunodeficiencies by intrathymic injection of nucleotide sequences |
| 03/12/2013 | US8394761 Methods for treating congestive heart failure |
| 03/12/2013 | US8394756 Methods of increasing RDCVF 1 or RDCVF 2 polypeptides in retinal cells |
| 03/12/2013 | US8394628 RNA sequence-specific mediators of RNA interference |
| 03/12/2013 | US8394414 Synthetic biodegradable microparticles incorporating a therapeutic, prophylactic or diagnostic agent having a diameter of 0.5-10 microns and release the agent at a pH of 6.0 or greater |
| 03/12/2013 | US8394411 Papillomavirus pseudoviruses for detection and therapy of tumors |
| 03/12/2013 | US8394390 Neisserial antigenic peptides |
| 03/12/2013 | US8394385 Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| 03/12/2013 | US8394384 Recombinant avian influenza vaccine and uses thereof |